Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

PharmaDrug announces $300,000 strategic investment in Sairiyo subsidiary by PharmaTher

Published 2023-07-18, 08:33 a/m
PharmaDrug announces $300,000 strategic investment in Sairiyo subsidiary by PharmaTher

Proactive Investors - PharmaDrug Inc (CSE:PHRX) has announced a $300,000 investment in its Sairiyo Therapeutics biotech subsidiary by PharmaTher Inc, a wholly-owned unit of PharmaTher Holdings (CSE:PHRM).

Under the agreement reached on July 17, 2023, PharmaDrug said PharmaTher will subscribe for 144,117,647 of Sairiyo’s common shares for a 49% stake in the company.

Sairiyo plans to use the investment funds for the ongoing development of cepharanthine as it finalizes production of the current good manufacturing practice (cGMP) batch of lead drug candidate PD-001 and prepares it for potential in-human trials, it added.

“We believe that aside from the financial contribution, PharmaTher's scientific and overall drug development acumen will provide a synergy that will ultimately yield the best value for shareholders for both the cepharanthine and psychedelic pharmaceutical programs,” PharmaDrug chairman and CEO Daniel Cohen said in a statement.

“This investment will enable PharmaDrug to reactivate its program and reaccelerate its cepharanthine development.”

As well as the investment, PharmaDrug said PharmaTher will also provide drug development, regulatory, clinical and scientific expertise for Sairiyo. While cepharanthine is the current prime focus, the company said Sairiyo's combined leadership will continue to develop its psychedelic assets, such as the N,N-Dimethyltryptamine (DMT) glaucoma initiatives and microneedle patch development that PharmaDrug and PharmaTher had already begun collaborating on.

PharmaDrug said it will also enter into a unanimous shareholders agreement with PharmaTher concerning their holdings of Sairiyo.

While the shareholders will be entitled to subscribe for any future new share issuances, it said that if it elects not to particulate in any new issuance, PharmaTher may increase its ownership from 49% to 51% with an investment of $250,000. Either side may increase its ownership by 10% for additional $100,000 investments and neither side may be diluted beyond a 10% carried interest, it added.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

PharmaDrug is a specialty pharmaceutical company focused on the research, development, and commercialization of controlled substances and natural medicines such as psychedelics and previously approved drugs.

Read more on Proactive Investors CA

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.